Nordic Life Science Days
Nordic Life Science Days | September 8-9, 2026 | Stockholm (SWE)
Nordic Life Science Days is Scandinavia’s largest life science event, held annually since 2013. The event brings together leading representatives of the biotechnology, pharmaceutical, and medical industries, as well as financial, research, administrative, and regulatory institutions from around the world.
This year’s topics highlight the event’s role in connecting global and Nordic perspectives across the life science ecosystem. In Stockholm, we will discuss:
- The future of biopharma partnerships
- The transformation of biotech innovation financing
- The growing role of strategic VC funds
- The rapid growth of innovation in China
- Investment opportunities in the medical technology sector
- Breakthrough therapies in CNS
Mabion will be exhibiting in partnership with the Polish Investment and Trade Agency. You can find us at the Polish Pavilion.
Biological Drug Development in Scandinavia
Hundreds of active pharma and biotech projects spanning preclinical and clinical phases. We are extremely excited to meet with companies looking to find new investors and partners. Mabion supports clinical projects from the early stages, so we are a partner supporting global expansion.
In Stockholm, Mabion will be represented by Judyta Suskiewicz, Director of Business Development. Judyta has been active in the Nordic region for many years, working on collaborations with biotech and pharma. She says the following about the prospects for this year’s event:
The Scandinavian biotechnology ecosystem is one of the most dynamic in the global market. Its impressive density of ideas and strong support network provide an exceptional foundation for scalable business growth. I am sure that Mabion can be a part of this growth as a trusted partner for Scandinavian companies. I believe that Nordic Life Science Days 2026 will be the perfect meeting place.
At Mabion, we are open to collaboration in drug substance manufacturing and process development for biologics. We have experience managing programs for the development of monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and subunit vaccines. We help smaller biotech companies enter the market faster and without regulatory challenges.
Look at the event website for more information.